永太科技(002326.SZ):擬建高級醫藥中間體、農藥中間體以及原藥項目
格隆匯5月27日丨永太科技(002326.SZ)公佈,為了拓展和強化公司在內蒙古地區的市場和業務佈局,擴大企業規模,增強公司整體實力和市場競爭優勢,內蒙古永太擬投資建設第二期項目,總投資8億元,形成年產14770噸高級醫藥中間體、農藥中間體以及原藥及聯產品的生產能力。
項目擬形成年產500噸BFAA、60噸C107、60噸C109、500噸CFA、500噸除蟲脲、800噸DCFBB、2000噸DFPA、500噸DMPT、200噸ETTP、1110噸C200、2600噸CAAME、590噸TCP、50噸5DCP、2000噸3DCP、1000噸C1201、100噸DFA、2000噸吡蚜酮、200噸TMNI以及聯產459噸80%硫酸、1228噸95%乙醇、8004噸30%鹽酸、187噸硫酸鈉、1770噸氯化鉀、15055噸硫酸鈣、7435氟化鉀的生產能力。
項目滿產後年新增收入277974.48萬元,年新增淨利潤25984.22萬元,税後財務內部收益率33.24%,税後投資回收期(含建設期)為4.7年。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.